References
Cho, K. J., Schepens, B., Moonens, K., Deng, L., Fiers, W., Remaut, H., & Saelens, X. (2016). Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody. J Virol, 90 (1), 611-615. doi:10.1128/JVI.02105-15
Cho, K. J., Schepens, B., Seok, J. H., Kim, S., Roose, K., Lee, J. H., . . . Kim, K. H. (2015). Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol, 89 (7), 3700-3711. doi:10.1128/jvi.02576-14
Deng, L., Chang, T. Z., Wang, Y., Li, S., Wang, S., Matsuyama, S., . . . Wang, B. Z. (2018). Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice. Proc Natl Acad Sci U S A, 115 (33), E7758-E7767. doi:10.1073/pnas.1805713115
Deng, L., Mohan, T., Chang, T. Z., Gonzalez, G. X., Wang, Y., Kwon, Y. M., . . . Wang, B. Z. (2018). Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat Commun, 9 (1), 359. doi:10.1038/s41467-017-02725-4
Ding, P., Jin, Q., Chen, X., Yang, S., Guo, J., Xing, G., . . . Zhang, G. (2019). Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.Int J Nanomedicine, 14 , 7533-7548. doi:10.2147/IJN.S218057
Ding, P., Jin, Q., Zhou, W., Chai, Y., Liu, X., Wang, Y., . . . Zhang, G. (2019). A Universal Influenza Nanovaccine for ”Mixing Vessel” Hosts Confers Potential Ability to Block Cross-Species Transmission. Adv Healthc Mater, 8 (16), e1900456. doi:10.1002/adhm.201900456
Ding, P., Zhang, T., Li, Y., Teng, M., Sun, Y., Liu, X., . . . Zhang, G. (2017). Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2. Int J Nanomedicine, 12 , 5239-5254. doi:10.2147/ijn.s140789
Dormitzer, P. R., Ulmer, J. B., & Rappuoli, R. (2008). Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol, 26 (12), 659-667. doi:10.1016/j.tibtech.2008.08.002
Gao, G. F. (2018). From ”A”IV to ”Z”IKV: Attacks from Emerging and Re-emerging Pathogens. Cell, 172 (6), 1157-1159. doi:10.1016/j.cell.2018.02.025
Khayat, R., Brunn, N., Speir, J. A., Hardham, J. M., Ankenbauer, R. G., Schneemann, A., & Johnson, J. E. (2011). The 2.3-angstrom structure of porcine circovirus 2. J Virol, 85 (15), 7856-7862. doi:10.1128/jvi.00737-11
Kim, K. H., Kwon, Y. M., Lee, Y. T., Kim, M. C., Hwang, H. S., Ko, E. J., . . . Kang, S. M. (2018). Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus.Vaccines (Basel), 6 (4). doi:10.3390/vaccines6040066
Kim, M. C., Lee, J. S., Kwon, Y. M., O, E., Lee, Y. J., Choi, J. G., . . . Kang, S. M. (2013). Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res, 99 (3), 328-335. doi:10.1016/j.antiviral.2013.06.010
Kim, M. C., Lee, J. W., Choi, H. J., Lee, Y. N., Hwang, H. S., Lee, J., . . . Kang, S. M. (2015). Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release, 210 , 208-216. doi:10.1016/j.jconrel.2015.05.278
Kim, M. C., Song, J. M., O, E., Kwon, Y. M., Lee, Y. J., Compans, R. W., & Kang, S. M. (2013). Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther, 21 (2), 485-492. doi:10.1038/mt.2012.246
Kolpe, A., Schepens, B., Fiers, W., & Saelens, X. (2017). M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines, 16 (2), 123-136. doi:10.1080/14760584.2017.1240041
Lekcharoensuk, P., Morozov, I., Paul, P. S., Thangthumniyom, N., Wajjawalku, W., & Meng, X. J. (2004). Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2. J Virol, 78 (15), 8135-8145. doi:10.1128/JVI.78.15.8135-8145.2004
Long, J. S., Mistry, B., Haslam, S. M., & Barclay, W. S. (2019). Host and viral determinants of influenza A virus species specificity. Nat Rev Microbiol, 17 (2), 67-81. doi:10.1038/s41579-018-0115-z
Lowen, A. C. (2017). Constraints, Drivers, and Implications of Influenza A Virus Reassortment. Annu Rev Virol, 4 (1), 105-121. doi:10.1146/annurev-virology-101416-041726
Petukhova, N. V., Gasanova, T. V., Stepanova, L. A., Rusova, O. A., Potapchuk, M. V., Korotkov, A. V., . . . Atabekov, J. G. (2013). Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Curr Pharm Des, 19 (31), 5587-5600. doi:10.2174/13816128113199990337
Qi, M., Zhang, X. E., Sun, X., Zhang, X., Yao, Y., Liu, S., . . . Cui, Z. (2018). Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection. Small, 14 (13), e1703207. doi:10.1002/smll.201703207
Rodriguez-Limas, W. A., Sekar, K., & Tyo, K. E. (2013). Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development.Curr Opin Biotechnol, 24 (6), 1089-1093. doi:10.1016/j.copbio.2013.02.008
Schepens, B., De Vlieger, D., & Saelens, X. (2018). Vaccine options for influenza: thinking small.Curr Opin Immunol, 53 , 22-29. doi:10.1016/j.coi.2018.03.024
Wang, D., Zhang, S., Zou, Y., Yu, W., Jiang, Y., Zhan, Y., . . . Yang, Y. (2018). Structure-Based Design of Porcine Circovirus Type 2 Chimeric VLPs (cVLPs) Displays Foreign Peptides on the Capsid Surface. Front Cell Infect Microbiol, 8 , 232. doi:10.3389/fcimb.2018.00232
Wang, Y., Deng, L., Gonzalez, G. X., Luthra, L., Dong, C., Ma, Y., . . . Wang, B. Z. (2020). Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice. Adv Healthc Mater, 9 (2), e1901176. doi:10.1002/adhm.201901176
Yong, C. Y., Yeap, S. K., Ho, K. L., Omar, A. R., & Tan, W. S. (2015). Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles. Int J Nanomedicine, 10 , 2751-2763. doi:10.2147/IJN.S77405